Progress on xenotransplantation and bioengineered organs, the potential next growth frontier for United Therapeutics
United Therapeutics is making a major strategic bet on xenotransplantation and bioengineered organs as its primary long-term growth driver. The is using genetically modified pig organs to reduce rejection risk — with its UHeart and UKidney programmes having already achieved transplants in living humans. In parallel, it is developing 3D-bioprinted…
Read More
Economic burden of pulmonary arterial hypertension in Switzerland, Plos One, April 28, 2026
A cross-sectional Swiss study involving 124 pulmonary arterial hypertension patients across six centres estimated the annual cost at nearly €139,000 per patient, with direct healthcare costs accounting for 78.5% of this figure — driven predominantly by pharmacological treatment, which alone represented 65% of total costs. Indirect costs, including productivity losses…
Read More
Exploring the potential of “synthetic” control arms in clinical trials to reduce trial size, speed up recruitment, cut costs, improve early stage decision making, The Scientist, April 25, 2026
Qureight, a data science company, is using synthetic control arms — trial groups generated from existing real-world and historical datasets rather than traditional placebo groups. Their approach involves repeatedly drawing random patient samples from external datasets and matching them to trial participants on key baseline characteristics, generating hundreds of potential…
Read More
Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026
Pulnovo Medical, a Shanghai-based company developing therapies for pulmonary hypertension and heart failure, has raised $100 million in a strategic financing round led by Medtronic, which has also entered into a separate commercial agreement with the company exploring future commercialisation opportunities. Pulnovo’s flagship product is the Pulmonary Artery Denervation (PADN)…
Read More
Join the “Global Pulmonary Hypertension Patient Hackathon” organised by the Global Allergy & Airways Patient Platform (GAAPP) and Latin Health Leaders (LDL) on June 10-11, 2026!
Within the framework of the PHA 2026 International Conference (June 11-14 in Dallas, Texas), the Global Allergy & Airways Patient Platform (GAAPP) and Latin Health Leaders (LDL) will convene the “Global Pulmonary Hypertension Patient Hackathon”, taking place on June 10 (full day) and June 11 (half day), with the strategic support of the Pulmonary Vascular Research…
Read More
The Canadian Pulmonary Hypertension Association, PHA Canada, launches its “PH Peer Mentor Program”, April 2026
The Canadian Pulmonary Hypertension Association (PHA Canada) has launched a “Pulmonary Hypertension Peer Mentor Program”, designed to connect patients and caregivers with trained volunteers. The peer mentors offer a supportive ear, share practical insights, and provide helpful resources based on their own lived experience with pulmonary hypertension. Read more on…
Read More
Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis, Health Quality of Life Outcomes, April 13, 2026
The importance of patient-reported outcome measures (PROMs) in assessing health-related QoL has been increasingly recognized, but their implementation remains inconsistent in clinical practice. A systematic review published on April 13, 2026 on Health Quality of Life Outcomes has synthesized the available evidence on the impact of pulmonary arterial hypertension on…
Read MoreGSK completes acquisition of 35Pharma, whose investigational drug HS235 for the treatment of pulmonary arterial hypertension targets the activin receptor signalling pathway
GSK has completed the acquisition of 35Pharma, a Canadian clinical-stage biopharmaceutical company. The key asset is HS235, a molecule targeting the activin receptor signalling pathway — the same pathway as sotatercept — designed for the treatment of pulmonary arterial hypertension. HS235 is engineered for greater selectivity than existing agents, with…
Read More
Understanding how the right heart catheterisation works, the UK Pulmonary Hypertension Association (PHA UK)’s video of the month, April 2026
The right heart catheter – also known as cardiac catheterisation, and abbreviated as RHC –is considered the “gold standard’ test to diagnose pulmonary arterial hypertension, and at follow up to monitor progress of the condition and efficacy of treatments. In this video Dr Charlie Elliott, from the Sheffield Pulmonary Vascular…
Read More
UK Pulmonary Hypertension Association opens Poetry Competition to the pulmonary hypertension community
The UK Pulmonary Hypertension Association (PHA UK) is inviting everyone in the pulmonary community to enter their Poetry Competition — patients, caregivers, family members, friends, and healthcare professionals alike. It’s free to enter. These are some of the topics suggested: 👉 Visit the PHA UK website to enter.
Read More
The latest edition of “Connections”, the Canadian Pulmonary Hypertension Association (PHA Canada)’s twice-yearly magazine, is dedicated to raising awareness of organ donation and transplant
This month, The Canadian Pulmonary Hypertension Association PHA Canada is raising awareness about the life-changing impact of organ and tissue donation. The newest issue of their magazine Connections is dedicated to Transplant & Pulmonary Hypertension, and it explores this important topic through stories, insights, and resources from the community. 👉…
Read More
CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30
One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is…
Read More
Walk4PH Nigeria: A Community Steps Up for Pulmonary Hypertension Awareness, May 16, 2026
Here is a short report: Walk4PH is a growing awareness initiative founded by Ayotunde Omitogun, a pulmonary hypertension patient and founder of the Cardiac Community, a Nigerian non-profit organisation dedicated to improving the lives of people living with heart and lung conditions. This year, Walk4PH has evolved into something larger…
Read More
The Canadian Pulmonary Hypertension Association (PHA Canada) launches an Advisory Council bringing together patients and caregivers to help shape its future programs and priorities
The Canadian Pulmonary Hypertension Association (PHA Canada) has recently announced the setting up of a “Patient Partner Advisory Council (PPAC)”—a new committee which brings together patients and caregivers to help shape the future of the pulmonary hypertension community. The founding members are Angèle Belliveau, Don Downey, Maureen Harper, Brooke Paulin, and…
Read More
Self-Image and pulmonary hypertension: a study supported by the UK Pulmonary Hypertension Association explores how living with the condition can shape the way patients see themselves
With the support of the UK Pulmonary Hypertension Association (PHA UK), trainee psychologist Jacob Pendrey, at Cardiff University in Wales, conducted a study exploring how pulmonary hypertension affects self-image — and the findings are both striking and important. Pulmonary hypertension is known to alter daily life not only through physical…
Read More
The US Pulmonary Hypertension Association, the PHA, celebrates its 35th anniversary this year, read more on the latest edition of its magazine Pathlight
As US Pulmonary Hypertension Association, celebrates its 35th anniversary this year, founders Judy and Ed Simpson reflect on the organization’s history in the latest issue of Pathlight magazine. Check out the timeline at this link The Pulmonary Hypertension Association (PHA) was founded in 1991 by three patients and a nurse…
Read More
Inhibikase Therapeutics begins pivotal phase 3 trial in pulmonary arterial hypertension, April 7, 2026
Inhibikase Therapeutics has enrolled the first patient in its global pivotal Phase 3 IMPROVE-PAH trial of IKT-001 for pulmonary arterial hypertension. The trial uses a two-part adaptive design: the first part evaluates change in pulmonary vascular resistance in approximately 140 patients over 12 weeks, followed by a second part focusing…
Read More
Review of Pulmonary Arterial Hypertension (PAH) research in 2025: key trends and what they mean for patients, Pulmonary Therapy, April 8, 2026
A descriptive analysis of 54 pulmonary arterial hypertension-related clinical studies registered on international platforms in 2025 was recently published in Pulmonary Therapeutics. The review reveals an evolving and increasingly sophisticated research landscape. Nearly two thirds of the studies were interventional and one third observational, with most involving pharmacological interventions. Most…
Read More
AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension with Interstitial Lung Disease (ILD-PH), April 9, 2026
AllRock Bio has dosed the first patients in its Phase 2a ROCSTAR trial, evaluating ROC-101 — a potential first-in-class oral pan-rho-associated protein kinase (ROCK) inhibitor — in patients with pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease. The open-label, multicenter, exploratory study will evaluate the safety, tolerability, and…
Read More
Pulmonary Hypertension Global Patient Survey (PHGPS), key insights and campaign pack
In October 2023, the Pulmonary Vascular Research Institute launched the Pulmonary Hypertension Global Patient Survey (PHGPS) to better understand the reality of what it is like to live with the condition worldwide. Almost 4,000 patients and carers from 90 countries took part in the survey and shared their experiences, which…
Read MoreSomething went wrong. Please refresh the page and/or try again.
Archive (1026) News (752) Save the date (5)
AI (3) America (17) Asia (13) biomarkers (3) BMPR2 (3) clinical trials (3) Colombia (3) CTEPH (7) Deutsch (3) diagnosis (9) diagnostics (3) Digital health (3) ELF (3) EMA (3) English (4) ERS (3) ESOT (4) Europe (34) Francais (9) genetics (4) German (4) Germany (3) health technology assessment (3) HTA (3) HTAP (5) Italiano (6) Latinamerica (14) Lungenhochdruck (3) PAH (9) PAHSSc (6) PH (3) PHA (11) PHA UK (8) QOL (3) quality of life (3) remote monitoring (4) RHC (4) right heart cath (2) right heart catheterisation (3) scleroderma (3) sotatercept (4) Spain (3) Telemedicine (3) Turkish (7) Türkçe (2)